M

McKesson

Supplies medicines and technology to healthcare teams

Principal AI Transformation Strategist

Full-TimeUpdated on 10/23/2026
€105k - €175k+ Annual bonus + Long-term incentive opportunities
Expert
Bachelor's
Cork, Ireland
Hybrid
AI & Machine Learning

About the job

Requirements
  • A degree or equivalent is required; the role typically requires 13+ years, including 8+ years of direct work-related experience. Fewer years may be required with relevant Master's or Doctorate qualifications.
  • 12–15+ years in AI, advanced analytics, data engineering, or technology transformation, including 7+ years guiding large-scale programmes.
  • Demonstrated success taking AI solutions from concept to scaled production in complex, multi-stakeholder enterprises.
  • Experience in regulated industries and comfort navigating compliance, risk, audit, and privacy requirements.
  • An advanced degree in a quantitative or technical field, such as Computer Science, Engineering, or Data Science, is preferred.
  • Relevant cloud, security, agile, or programme management certifications are a plus.
  • Ability to translate corporate objectives into a multi-year, value-backed AI portfolio.
  • Expertise across AI/ML architecture, model lifecycle from data readiness to deployment and monitoring, and operations in regulated environments.
  • Ability to frame complex technical topics into clear business narratives that drive prioritisation and funding decisions.
  • Hands-on familiarity with MLOps/ModelOps platforms, data quality controls, model risk management, and responsible AI practices.
  • Ability to establish standards, reusable frameworks, and decision guardrails across business units.
  • Ability to design and review KPIs/OKRs tracking adoption, time-to-value, reliability, safety, and total cost of ownership.
  • Vendor and platform evaluation skills, including balancing build versus buy, speed versus control, and innovation versus risk.
  • Written and verbal communication skills, including presenting to VP/SVP audiences and enterprise steering committees.
  • Ability to communicate clearly and credibly, simplify complexity for decision makers, anticipate broader effects, own outcomes, build cross-functional trust, adapt to evolving technology, and balance ambition with feasibility.
Responsibilities
  • Define and maintain the enterprise AI portfolio roadmap, sequencing initiatives to maximise compound value and reduce duplicated effort.
  • Shape scope and success criteria for high-impact programmes, coach delivery leaders, and hold teams accountable for outcomes.
  • Remove structural blockers involving operating models, data access, and funding mechanisms to accelerate scaled delivery.
  • Define benefits realisation plans with clear baselines and target metrics, including productivity, quality, cycle time, and revenue uplift.
  • Establish standard dashboards for executive consumption and ensure telemetry is reliable, auditable, and explains variance.
  • Lead quarterly value reviews and recommend portfolio rebalancing based on performance and risk.
  • Advise product and engineering leaders on shaping roadmaps for scale, auditability, and measurable outcomes.
  • Represent McKesson Technology in executive steering committees and enterprise governance forums.
  • Influence business-unit leaders, Compliance, Risk, Security, and Legal to align on standards and guardrails.
  • Co-lead the definition and rollout of Responsible AI, model risk, and policy controls, ensuring controls are effective and developer-friendly.
  • Chair or materially contribute to model review boards and serve as an escalation point for high-risk AI deployments.
  • Evaluate and recommend technical approaches, tools, and platforms that improve reliability, safety, and time-to-value.
  • Guide reference architectures for generative and predictive AI, ensuring patterns are secure, observable, and cost-aware.
  • Represent McKesson in strategic partner engagements, technology councils, and cross-industry working groups.
  • Scan the market and regulatory landscape and translate implications into pragmatic internal guidance.

About the company

McKesson distributes medicines and medical supplies to pharmacies, hospitals and other care providers, alongside services that connect drug manufacturers with patients. Its specialty businesses support community cancer care and clinical research, extending its work beyond moving products through warehouses. The company buys drugs and supplies from manufacturers for resale, while its software helps pharmacies manage inventory and healthcare teams secure insurance approval for prescriptions. It also sells practice management and patient support services to clinicians and drugmakers. McKesson traces its business roots to 1833 and is headquartered in Irving, Texas.

Company Size

10,001+

Company Stage

IPO

Headquarters

Irving, Texas

Founded

1833

Get referred to McKesson

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Reinvestment has cash behind it: McKesson reported $6.2 billion operating cash flow for fiscal 2026 in May 2026.
  • Specialty expansion drives growth: McKesson reported 31% higher fiscal 2026 Oncology and Multispecialty sales in May 2026.
  • Technical candidates have openings: McKesson lists 154 information technology jobs on its career site in October 2026.

What critics are saying

  • One customer holds bargaining power: CVS generated 24% of McKesson's fiscal 2026 revenue, reported in May 2026.
  • Technology jobs face cuts: McKesson approved prescription technology headcount reductions during January through March 2026.
  • Medical supply careers face separation: McKesson outlined a planned Medical-Surgical IPO alongside Apollo's investment agreement in April 2026.

What makes McKesson unique

  • McKesson backs independent ownership: its Health Mart franchise supports pharmacies that remain independently owned and operated.
  • Generic purchasing has a retail partner: McKesson and Walmart jointly source medicines through ClarusONE.
  • McKesson reaches prescribing workflows: CoverMyMeds processes insurance approval requests free for clinicians across all plans and medications.

Help us improve and share your feedback! Did you find this helpful?

Benefits

  • Performance Bonus
  • 401(k) Company Match

Growth & Insights and Company News

6 month growth

0%

1 year growth

0%

2 year growth

0%
Yahoo Finance
Oct 23rd, 2026
Fastenal and McKesson are cash-rich stocks to buy this week; Carlisle is one to avoid

StockStory has named two cash-producing stocks to buy this week and one to avoid, saying cash generation alone doesn't make a company a winner. The stock to avoid is Carlisle (NYSE:CSL), a construction materials and weatherproofing maker with a 17% trailing 12-month free cash flow margin. StockStory cites weak organic revenue growth, projected sales growth of 5.8%, and annual earnings per share growth of just 3.6% over two years. Shares trade at $352.84, or 15.1x forward earnings. Fastenal (NASDAQ:FAST), with a 13% free cash flow margin, has a 45.3% gross margin, a 20.5% operating margin, and a 32.3% return on capital. Its shares trade at $52.32, or 38x forward earnings. McKesson (NYSE:MCK) has a 1.5% margin. Sales grew 14.5% annually over two years, and revenue reached $411 billion. Shares trade at $1,010, or 21.8x forward earnings.

AD HOC NEWS
Oct 15th, 2026
McKesson commits $1.4B for 49% stake in Option Care at $5.8B valuation

McKesson will invest $1.4 billion for a 49% minority stake in Option Care Health, under an agreement announced on October 6, 2026. The deal values Option Care at an enterprise value of $5.8 billion. Clayton, Dubilier & Rice will hold about 51%. Option Care will stay separately managed, while McKesson keeps a framework to acquire the remaining interest later, subject to conditions and regulatory approvals. In its first fiscal 2027 quarter, McKesson reported revenue of $105.38 billion, up 7.7% year on year, and adjusted earnings per share of $9.93. It will report second-quarter results on November 4, 2026.

TradingView
Oct 6th, 2026
CD&R and McKesson to acquire Option Care Health.

CD&R and McKesson to acquire Option Care Health. WASHINGTON (dpa-AFX) - CD&R, McKesson (MCK) and Option Care Health (OPCH) have entered into a definitive agreement, under which CD&R and McKesson will acquire Option Care Health for $32.05 per share, reflecting a total enterprise value of approximately $5.8 billion. Upon completion, Option Care Health will become a privately held company. CD&R will hold a majority interest of approximately 51% in Option Care Health and McKesson will invest approximately $1.4 billion for a minority interest of approximately 49%. The deal establishes a framework for McKesson's future acquisition of CD&R's interest in Option Care Health, subject to specified conditions and regulatory approvals. Option Care Health is an independent provider of home and alternate site infusion services. In pre-market trading on NasdaqGS, Option Care shares are up 20.50 percent to $28.16. For More Such Health News, visit rttnews.com. Copyright(c) 2026 RTTNews.com. All Rights Reserved Copyright RTT News/dpa-AFX Read the full article

McKesson Corporation
Oct 1st, 2026
McKesson wins Vizient's 2026 Distribution Excellence Award.

McKesson wins Vizient's 2026 Distribution Excellence Award. Vizient's 2026 Distribution Excellence Award honors suppliers that consistently deliver exceptional service and value to Vizient member health systems. September 29, 2026 In September 2026, Vizient presented McKesson with the 2026 Distribution Excellence Award at the Vizient Connections Summit in Las Vegas. The award recognizes suppliers that demonstrate superior service, support, reliability, ethics, and integrity in collaboration with Vizient.[1] Vizient, a member-owned healthcare performance improvement company, works with thousands of not-for-profit health systems and affiliates. Through its network, Vizient connects healthcare leaders with data, insights, and supplier relationships designed to drive value across the enterprise. For McKesson, the recognition reflects years of building a strategic, enterprise-wide relationship with Vizient and its member organizations at a time when health systems increasingly rely on collaborative partnerships to navigate complexity across pharmacy, supply chain, and clinical operations. Ali Cobb, Vice President of Health Systems National Accounts for McKesson Health Systems, has been central to strengthening collaboration and identifying new ways to support member needs. As workforce pressures, financial constraints, and supply chain challenges continue to shape healthcare, strong strategic partnerships remain critical to helping health systems build resilience and advance patient health. This award reflects a shared commitment by Vizient and McKesson to help health systems meet today's demands while preparing for what's next, together.

JH Consulting Online
Sep 22nd, 2026
Cara McDonough joins McKesson Medical-Surgical as Chief Product Strategy & Supplier Partnerships Officer.

Cara McDonough joins McKesson Medical-Surgical as Chief Product Strategy & Supplier Partnerships Officer. September 22, 2026- McKesson Medical-Surgical has announced that Cara McDonough has joined the organization as Chief Product Strategy & Supplier Partnerships Officer, effective September 14, 2026. In this role, Cara will lead McKesson Medical-Surgical's Product Strategy and Supplier Partnerships teams, guiding supplier relationship strategy and portfolio development across the company's Private Label, Pharmaceutical, Consumer Markets, and Laboratory businesses as a member of the Executive Committee. Cara brings 20 years of experience leading and growing product-focused organizations. Throughout her career, she has held senior leadership positions with nationally recognized companies, driving merchandising, private label, product strategy, and commercial growth across multiple channels, including B2B, e-commerce, and retail. Her experience building differentiated product portfolios, strengthening supplier relationships, and delivering profitable growth aligns closely with the organization's long-term strategy. As McKesson Medical-Surgical continues evolving its business, Cara's leadership will help further strengthen supplier partnerships and support the organization's commitment to delivering innovative solutions and value to customers.